Burley, who takes a GLP-1 himself, tells Forbes the drug ads say little about training and that gyms should be ready for people on them.
Recap by typeshit. Full story at Forbes.
BMO's Evan Seigerman expects US share losses to weigh on Ozempic sales, while the 25% CagriSema figure comes from a post-hoc subgroup, not the full trial's 22.7%.
Beauty companies are reportedly exploring products aimed at facial changes linked to rapid weight loss on GLP-1 drugs.
A search page for retatrutide news with no specific story attached, so there is little new beyond recent coverage.
2:06:48
A live Q&A stream from DOWNSIZED taking viewer questions about GLP-1 medications, including Zepbound, Wegovy and Foundayo.
MedPage Today
A mental health news roundup points to a New York Times report that patients with eating disorders have little protection as GLP-1 use grows.
The Havre de Grace center opened a research building and will test whether the pairing cuts alcohol cravings. The study starts in early 2027, results about two years later.
Loading…